TBPH

Theravance Biopharma, Inc. (TBPH) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Theravance Biopharma is a biopharmaceutical company focused on the development and commercialization of medicines, primarily YUPELRI (revefenacin) for COPD and the investigational drug ampreloxetine for Multiple System Atrophy (MSA). The company operates under a strategic review to unlock shareholder value and recently separated the roles of Chair and CEO.

Key Financial Metrics

Note: Revenue is derived primarily from the Viatris collaboration agreement regarding YUPELRI. The company has no long-term debt.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 7% in Q3 and 14% in the first nine months of 2024 compared to the prior year, driven by a 7% increase in YUPELRI net sales (implied 35% share) and lower costs incurred by Viatris.
• Expense Management: Research and Development (R&D) expenses decreased 13% year-over-year for the nine-month period due to the discontinuation of certain research activities in 2023. However, Q3 R&D expenses increased 12% due to the progression of the ampreloxetine Phase 3 study (CYPRESS).
• Impairment Charges: The company recognized non-cash impairment charges of $1.6 million in Q3 and $4.5 million for the nine months ended September 30, 2024, related to vacant laboratory space and leasehold improvements. There were no such charges in the prior year periods.
• Share Repurchases: The company completed its $325.3 million capital return program in January 2024. Financing cash outflows dropped significantly from $168.3 million in the prior year to $2.1 million in the current nine-month period.

Outlook, Risks, and Management Commentary

• Liquidity: Management expects cash, cash equivalents, and marketable securities ($91.4 million) to be sufficient to fund operations for at least the next 12 months.
• YUPELRI Performance: Q3 2024 YUPELRI net sales reached an all-time high of $62.2 million (100% recorded by Viatris), driven by a 14% increase in customer demand and improved market share in hospital and community settings.
• Ampreloxetine Development: The Phase 3 CYPRESS study for ampreloxetine in MSA patients is ongoing. Final patient enrollment is anticipated in mid-2025, with top-line data expected approximately six months thereafter.
• TRELEGY Economic Interest: The company retains an economic interest in GSK's TRELEGY. Global net sales for TRELEGY grew 17% in Q3 and 30% in the first nine months of 2024. The company is eligible for potential milestone payments totaling $200 million based on sales thresholds.
• Patent Litigation: As of October 31, 2024, the company settled litigation with five generic companies regarding YUPELRI, granting licenses for generic launch on or after April 23, 2039. Litigation against three remaining generic companies remains pending.
• Strategic Review: A Strategic Review Committee has been formed to assess strategic alternatives, including those related to YUPELRI, ampreloxetine, and TRELEGY.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $91.4 million cash balance against the projected burn rate for the ampreloxetine Phase 3 study and commercialization preparations.
• Patent Expiry & Settlements: Review the terms of the settlements with generic manufacturers and the timeline for the remaining patent litigation to assess the risk of earlier generic entry than the 2039 date.
• TRELEGY Milestone Triggers: Monitor GSK's TRELEGY sales performance against the $2.86 billion and $3.21 billion thresholds required to trigger the next $25 million or $50 million milestone payments.
• Impairment Risks: Assess the status of the remaining vacant laboratory space and the likelihood of further impairment charges if subleasing efforts do not materialize.
• Strategic Alternatives: Monitor updates from the Strategic Review Committee regarding potential transactions or changes in corporate structure.